320 related articles for article (PubMed ID: 24569856)
41. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
42. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
Reguera-Nuñez E; Man S; Xu P; Kerbel RS
Angiogenesis; 2018 Nov; 21(4):793-804. PubMed ID: 29786782
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
44. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
[TBL] [Abstract][Full Text] [Related]
45. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
46. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
[TBL] [Abstract][Full Text] [Related]
47. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
[TBL] [Abstract][Full Text] [Related]
49. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
Kerbel RS
Cancer Res Treat; 2007 Dec; 39(4):150-9. PubMed ID: 19746237
[TBL] [Abstract][Full Text] [Related]
50. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
Creemers GJ; Bolis G; Gore M; Scarfone G; Lacave AJ; Guastalla JP; Despax R; Favalli G; Kreinberg R; Van Belle S; Hudson I; Verweij J; Ten Bokkel Huinink WW
J Clin Oncol; 1996 Dec; 14(12):3056-61. PubMed ID: 8955650
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
52. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
Koensgen D; Stengel D; Belau A; Klare P; Oskay-Oezcelik G; Steck T; Camara O; Mustea A; Sommer H; Coumbos A; Bogenrieder T; Lichtenegger W; Sehouli J;
Cancer Chemother Pharmacol; 2008 Aug; 62(3):393-400. PubMed ID: 17922272
[TBL] [Abstract][Full Text] [Related]
53. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
Tang TC; Man S; Xu P; Francia G; Hashimoto K; Emmenegger U; Kerbel RS
Neoplasia; 2010 Nov; 12(11):928-40. PubMed ID: 21076618
[TBL] [Abstract][Full Text] [Related]
54. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Dy GK; Infante JR; Eckhardt SG; Novello S; Ma WW; Jones SF; Huff A; Wang Q; Suttle AB; Ottesen LH; Adjei AA; Burris HA
Invest New Drugs; 2013 Aug; 31(4):891-9. PubMed ID: 23135778
[TBL] [Abstract][Full Text] [Related]
55. Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment.
Chung SW; Kim GC; Kweon S; Lee H; Choi JU; Mahmud F; Chang HW; Kim JW; Son WC; Kim SY; Byun Y
Biomaterials; 2018 Nov; 182():35-43. PubMed ID: 30103170
[TBL] [Abstract][Full Text] [Related]
56. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.
Clarke-Pearson DL; Van Le L; Iveson T; Whitney CW; Hanjani P; Kristensen G; Malfetano JH; Beckman RA; Ross GA; Lane SR; DeWitte MH; Fields SZ
J Clin Oncol; 2001 Oct; 19(19):3967-75. PubMed ID: 11579118
[TBL] [Abstract][Full Text] [Related]
57. Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
Ricci JW; Lovato DM; Severns V; Sklar LA; Larson RS
Mol Cancer Ther; 2016 Dec; 15(12):2853-2862. PubMed ID: 27671528
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
[TBL] [Abstract][Full Text] [Related]
59. Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer.
Aljuffali IA; Mock JN; Costyn LJ; Nguyen H; Nagy T; Cummings BS; Arnold RD
Cancer Biol Ther; 2011 Sep; 12(5):407-20. PubMed ID: 21709443
[TBL] [Abstract][Full Text] [Related]
60. A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.
Carter JS; Downs LS
Int J Clin Oncol; 2011 Dec; 16(6):666-70. PubMed ID: 21556801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
